Sichenzia Ross Friedman Ference LLP Represents Tonix Pharmaceuticals Holding Corp. on $20.1M Public Offering
Press Release – New York – July 17, 2015 – New York-based securities and corporate law firm Sichenzia Ross Friedman Ference LLP announced today that the firm represented Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP), a clinical-stage pharmaceutical company focused on products to treat common disorders of the central nervous system, in an underwritten public offering of 2,325,000 shares of its common stock, as well as the sale of 348,750 additional shares pursuant to the full exercise of the over-allotment option granted to the underwriters. The shares were sold to the public at an offering price of $7.50 per share resulting in gross proceeds to Tonix of approximately $20.1 million.
The Sichenzia Ross Friedman Ference LLP team was led by Partners Marc J. Ross and James M. Turner. Roth Capital Partners and Oppenheimer & Co. acted as joint underwriters and Janney Montgomery Scott acted as co-manager in this offering.
Visit SRF's LinkedIn page
Latest posts by Sichenzia Ross Ference LLP (see all)
- Founding Partner Gregory Sichenzia Featured in Business Insider Discussing the Legal Aftermath for Tesla - September 19, 2018
- Sichenzia Ross Ference LLP Acts as Principal Attorney Liaison for AusCann Group Holdings Ltd on OTCQX Listing - September 15, 2018
- Sichenzia Ross Ference LLP Acts as Principal Attorney Liaison for Zelda Therapeutics Ltd on OTCQX Listing - September 15, 2018